Risk of death associated with antipsychotic drug dispensing in residential aged care facilities

References

• Margallo-Lana M, Swann J, O'Brien J, et al. Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. Int J Geriatr Psychiatry 2001; 16: 39–44
   PubMed Web of Science ®Google Scholar
• Snowdon J, Day S, Baker W. Why and how antipsychotic drugs are used in 40 Sydney nursing homes. Int J Geriatr Psychiatry 2005; 20: 1146–1152
   PubMed Web of Science ®Google Scholar
• Bronskill SE, Anderson GM, Sykora K, et al. Neuroleptic drug therapy in older adults newly admitted to nursing homes: incidence, dose and specialist contact. J Am Geriatr Soc 2004; 52: 749–755
   PubMed Web of Science ®Google Scholar
• Brodaty H, Draper B, Low L-F. Behavioural and psychological symptoms of dementia: a seven-tiered model of service delivery. Med J Aust 2003; 178: 231–234
   PubMed Web of Science ®Google Scholar
• De Deyn P, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999; 53: 946–955
   PubMed Web of Science ®Google Scholar
• Katz I, Jeste D, Mintzer J, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 1999; 60: 107–115
   PubMed Web of Science ®Google Scholar
• Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 64: 134–143
   PubMed Web of Science ®Google Scholar
• Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2000; 57: 968–977
   PubMed Web of Science ®Google Scholar
• De Deyn PP, Katz IR, Brodaty H, Lyons B, Greenspan A, Burns A. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. Clin Neurol Neurosurg 2005; 107: 497–508
   PubMed Web of Science ®Google Scholar
• Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A. Behavioural symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987; 48 S5: 9–15
   Google Scholar
• Mintzer JE, Greenspan A, Caers I, et al. Risperidone in the treatment of psychosis of Alzheimer's disease: results from a prospective clinical trial. Am J Geriatr Psychiatry 2006; 14: 280–291
   PubMed Web of Science ®Google Scholar
• Teri L, Logsdon RG, Peskind E, et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology 2000; 55: 1247–1248
   PubMed Web of Science ®Google Scholar
• De Deyn P, Jeste DV, Swanink R, et al. Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study. J Clin Psychopharmacol 2005; 25: 463–467
   PubMed Web of Science ®Google Scholar
• Deberdt WG, Dysken MW, Rappaport SA, et al. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am J Geriatr Psychiatry 2005; 13: 722–730
   PubMed Web of Science ®Google Scholar
• Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006; 355: 1525–1538
   PubMed Web of Science ®Google Scholar
• Kryzhanovskaya LA, Jeste DV, Young CA, et al. A review of treatment-emergent adverse events during olanzapine clinical trials in elderly patients with dementia. J Clin Psychiatry 2006; 67: 933–945
   PubMed Web of Science ®Google Scholar
• Schneider LS, Dagerman KS, Inse P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934–1943
   PubMed Web of Science ®Google Scholar
• Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005; 353: 2335–2341
   PubMed Web of Science ®Google Scholar
• Hollis, J, Grayson, D, Forrester, L, Brodaty, H, Touyz, S, Cumming, RG. Antipsychotic medication dispensing and risk of death in veterans and war widows. Am J Geriatr Psychiatry 2007; (in press).
   PubMed Web of Science ®Google Scholar
• Herrmann N, Mamdani M, Lanctot KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 2004; 161: 1113–1115
   PubMed Web of Science ®Google Scholar
• Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005; 330: 445–451
   PubMed Web of Science ®Google Scholar
• Finkel S, Kozma C, Long S, et al. Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. Int Psychogeriatr 2005; 17: 617–629
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. [Accessed 19 July 2007.]. Rockville: MD, US Department of Health and Human Services. Available from URL:, , http://www.fda.gov/bbs/topics/ANSWERS/2005/ANS01350.html
   Google Scholar
• Royal College of Psychiatrists Faculty for the Psychiatry of Old Age. Summary: guidance for the management of behavioural and psychiatric symptoms in dementia and the treatment of psychosis in people with history of stroke/TIA. [Accessed 10 February 2006.]. London: Royal College of Psychiatists. Available from URL:, , http://www.rcpsych.ac.uk/college/faculty/oap/BPSD.pdf
   Google Scholar
• Alexopoulos GS, Streim J, Carpenter D, Docherty JP. Expert consensus guideline series: using antipsychotic agents in older patients. J Clin Psychiatry 2004; 65: 5–19
   PubMed Web of Science ®Google Scholar
• Lonergan, ET, Luxenberg, J. Valproate preparations for agitation in dementia. Cochrane Database Syst Rev 2004:1–34.
   Google Scholar
• Tariot PN, Erb R, Podgorski CA, Cox C. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998; 155: 54–61
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001; 154: 854–864
   PubMed Web of Science ®Google Scholar
• APA. Practice guideline for the treatment of patients with delirium. Am J Psychiatry 1999; 156 (Suppl.):1–20.
   Google Scholar
• Skrobik YK, Bergeron N, Dumont M, Gottfried SB. Olanzapine vs haloperidol: treating delirium in a critical care setting. Intensive Care Med 2004; 30: 444–449
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, White T, Nasrallah A. Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol. Am J Geriatr Psychiatry 2004; 12: 437–439
   PubMed Web of Science ®Google Scholar
• Barnett MJ, Perry PJ, Alexander B, Kaboli PJ. Risk of mortality associated with antipsychotic and other neuropsychiatric drugs in pneumonia patients. J Clin Psychopharmacol 2006; 26: 182–187
   PubMed Web of Science ®Google Scholar
• Hennessy S, Bilker WB, Knauss JS, et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ 2002; 325: 1070–1075
   PubMed Web of Science ®Google Scholar
• Ray WA, Meredith S, Thapa PB, Meador KG. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001; 58: 1161–1168
   PubMed Web of Science ®Google Scholar
• Drici M, Wang W, Liu X, Woosley R, Flockhart D. Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. J Clin Psychopharmacol 1998; 18: 477–481
   PubMed Web of Science ®Google Scholar
• Devanand DP, Marder K, Michaels KS, et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am J Psychiatry 1998; 155: 1512–1520
   PubMed Web of Science ®Google Scholar
• Wada H, Nakajoh K, Satoh-Nakagawa T, Suzuki T. Risk factors of aspiration pneumonia in Alzheimer's disease patients. Gerontology 2001; 47: 271–277
   PubMed Web of Science ®Google Scholar